Search for: "Akorn Inc."
Results 21 - 40
of 54
Sorted by Relevance
|
Sort by Date
30 Sep 2019, 9:02 am
Akorn, Inc., No. 18-1418 (Whether no-opinion judgments comply with 35 U.S.C. [read post]
9 Jul 2019, 6:00 am
Akorn, Inc., Consol. [read post]
24 Jan 2012, 6:34 pm
Apotex, Inc., 540 F.3d 1353 (Fed. [read post]
20 Jul 2018, 11:44 pm
TevaPharmaceuticals USA, Inc., and Akorn, Inc. [read post]
15 May 2019, 9:24 am
Akorn, Inc., No. 18-1418 (Supreme Court 2019) with the following two questions: Whether 35 U.S.C. [read post]
23 Jul 2018, 2:38 pm
Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AKORN, Inc. [read post]
25 Apr 2012, 9:05 am
The owners of the three approved ANDAs for generic oral vancomycin—Akorn, Incorporated (“Akorn”), Watson Laboratories, Inc. [read post]
30 Nov 2016, 10:22 am
Defendant Akorn, Inc., a generic drugmaker based in Lake Forest, Illinois, filed an Abbreviated New Drug Application (“ANDA”) with the U.S. [read post]
21 Jan 2020, 6:20 am
In so holding, Chancellor Andre Bouchard signaled that last year’s Court of Chancery decision in Akorn, Inc. v. [read post]
8 Oct 2018, 3:01 am
While it’s also used in insecticides, it’s not poisonous for humans…” [Aimee Picchi, CBS News on suit claiming that LaCroix flavored water wrongly claims “all natural” status] “Appeals Court Strikes $8.7M in Legal Fees Based on Coupons in Class Action Settlement” [Ted Frank objection in ProFlowers and RedEnvelope class action; Amanda Bronstad, The Recorder] “Judge: Lawyers must justify fee requests for investor suits withdrawn vs… [read post]
12 Sep 2022, 8:35 am
Green Farms, Inc. [read post]
28 Dec 2019, 2:37 pm
” In Channel Medsystems, Inc. v. [read post]
19 Apr 2011, 8:23 am
ANDA sponsor Akorn, Inc. [read post]
8 Oct 2019, 9:44 am
Akorn, Inc., No. 18-1418 (propriety of R.36 judgments; obviousness) Imperium IP Holdings (Cayman), Ltd. v. [read post]
26 Jun 2019, 4:12 pm
Durkin, exercising his “inherent authority” and acting at the urging of an objecting shareholder, has “abrogated” the settlement of the litigation arising out of the acquisition of Akorn , Inc. by Frensenius Kabi AG, and ordered the plaintiffs’ lawyers to return to Akorn their $322,000 mootness fee, ruling that the additional disclosures to which the company agreed were “worthless to shareholders” and that the underlying… [read post]
22 Oct 2019, 1:53 pm
Ted Frank, an Akorn shareholder, moved to intervene and object to the fee. [read post]
19 Oct 2017, 10:29 am
” Generic drug manufacturers Teva Pharmaceuticals USA, Inc.; Akorn, Inc.; Mylan, Inc.; and Mylan Pharmaceuticals, Inc., that wish to manufacture and sell bioequivalent drugs having the same components as Restasis challenged that the patents asserted by Allergan are invalid in defense to a patent infringement suit filed by Allergan. [read post]
19 Oct 2017, 10:29 am
” Generic drug manufacturers Teva Pharmaceuticals USA, Inc.; Akorn, Inc.; Mylan, Inc.; and Mylan Pharmaceuticals, Inc., that wish to manufacture and sell bioequivalent drugs having the same components as Restasis challenged that the patents asserted by Allergan are invalid in defense to a patent infringement suit filed by Allergan. [read post]
19 Jun 2019, 6:18 am
Akorn, Inc., No. 18-1418 (R.36 judgments; holistic approach to obviousness) Glasswall Solutions Limited, et al. v. [read post]
31 Dec 2018, 4:00 am
Canadian Class Actions Monitor Timely DisclosureThe Big MAC: Affirmed Days ago, the Supreme Court of the State of Delaware issued an order succinctly affirming the Delaware Court of Chancery’s judgment from October this year that found Fresenius Kabi AG had no obligation to close its proposed merger with Akorn, Inc. and Fresenius properly terminated the merger agreement on April 22, 2018 largely as a result of Akorn having suffered a material adverse effect… [read post]
